Mesoblast Limited Cash Flow Conversion Efficiency

Latest as of June 2023: -0.032x

Mesoblast Limited cash flow conversion efficiency. Based on the latest financial reports, Mesoblast Limited (LWB) has a cash flow conversion efficiency ratio of -0.032x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-16.28 Million ≈ $-19.03 Million USD) by net assets (€501.84 Million ≈ $586.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Mesoblast Limited (2014–2025)

Cash flow conversion efficiency of Mesoblast Limited from 2014 to 2025. This chart illustrates how Mesoblast Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Mesoblast Limited for real-time trading data and today's change.

Mesoblast Limited Cash Flow Conversion Ratio Explained

Mesoblast Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Mesoblast Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mesoblast Limited ranked by their cash flow conversion efficiency. Also see Mesoblast Limited market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Essence Fastening Systems (Shanghai) Co. Ltd. SHE:301005	-0.008x
Huabao Flavours & Fragrances Co Ltd Class A SHE:300741	0.003x
Odontoprev S.A SA:ODPV3	0.005x
CoCreation Grass Co Ltd SHG:605099	0.002x
Soulbrain Co. Ltd KQ:357780	0.047x
Modern Times Group Mtg AB ST:MTG-B	0.079x
Molymet SN:MOLYMET	0.314x
Guangzhou SiE Consulting Co Ltd SHE:300687	0.006x

Annual Cash Flow Conversion Efficiency for Mesoblast Limited (2014–2025)

The table below shows the annual cash flow conversion efficiency of Mesoblast Limited from 2014 to 2025. Review LWB free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	€597.44 Million ≈ $698.47 Million	€-49.95 Million ≈ $-58.40 Million	-0.084x	+17.12%
2024-06-30	€480.36 Million ≈ $561.59 Million	€-48.46 Million ≈ $-56.65 Million	-0.101x	+19.98%
2023-06-30	€501.84 Million ≈ $586.70 Million	€-63.27 Million ≈ $-73.97 Million	-0.126x	+4.74%
2022-06-30	€497.04 Million ≈ $581.10 Million	€-65.78 Million ≈ $-76.91 Million	-0.132x	+23.63%
2021-06-30	€581.40 Million ≈ $679.71 Million	€-100.75 Million ≈ $-117.79 Million	-0.173x	-68.88%
2020-06-30	€549.33 Million ≈ $642.22 Million	€-56.37 Million ≈ $-65.90 Million	-0.103x	+14.59%
2019-06-30	€481.05 Million ≈ $562.40 Million	€-57.79 Million ≈ $-67.56 Million	-0.120x	+12.56%
2018-06-30	€546.01 Million ≈ $638.34 Million	€-75.01 Million ≈ $-87.70 Million	-0.137x	+25.64%
2017-06-30	€516.77 Million ≈ $604.15 Million	€-95.47 Million ≈ $-111.62 Million	-0.185x	-10.89%
2016-06-30	€528.16 Million ≈ $617.48 Million	€-88.00 Million ≈ $-102.88 Million	-0.167x	+22.83%
2015-06-30	€467.99 Million ≈ $547.13 Million	€-101.04 Million ≈ $-118.12 Million	-0.216x	-55.40%
2014-06-30	€539.18 Million ≈ $630.36 Million	€-74.91 Million ≈ $-87.57 Million	-0.139x	--

About Mesoblast Limited

F:LWB Germany Biotechnology

Market Cap

$1.95 Billion

€1.67 Billion EUR

Market Cap Rank

#6832 Global

#994 in Germany

Share Price

€1.29

Change (1 day)

-5.24%

52-Week Range

€1.08 - €1.71

All Time High

€3.48